According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- the communication between Hims and the pharmaceutical company Novo Nordisk A/S (“Novo”) would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers;
- Novo approved of Hims’ offerings of compounded semaglutide products under the “personalization” exception;
- branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and
- defendants made positive statements about the Novo partnership and Hims users’ ongoing access to Wegovy alongside compounded semaglutide products.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
